Related Experiment Video
Updated: Dec 20, 2025

08:05
Lung CT Segmentation to Identify Consolidations and Ground Glass Areas for Quantitative Assesment of SARS-CoV Pneumonia
Published on: December 19, 2020
14.6K
Any unique image biomarkers associated with COVID-19?
Jiantao Pu1, Joseph Leader2, Andriy Bandos3
1Department of Radiology, University of Pittsburgh, Pittsburgh, PA, 15213, USA. puj@upmc.edu.
European Radiology
|May 29, 2020
Summary
Chest CT scans show moderate ability to distinguish COVID-19 from pneumonia. Artificial intelligence models can identify non-COVID-19 cases, aiding in targeted decision-making for pneumonia diagnosis.
Area of Science:
- Radiology and Medical Imaging
- Artificial Intelligence in Medicine
- Infectious Diseases
Background:
- Distinguishing COVID-19 from community-acquired pneumonia (CAP) using chest CT is crucial for patient management.
- Identifying unique imaging biomarkers for COVID-19 on CT scans is an ongoing area of research.
Purpose of the Study:
- To define unique chest CT infiltrative features associated with COVID-19.
- To evaluate the diagnostic performance of artificial intelligence (AI) models and human experts in differentiating COVID-19 from CAP on CT scans.
Main Methods:
- Retrospective collection of chest CT exams from 151 COVID-19 patients and 497 CAP patients.
- Development and testing of 3D convolutional neural network (CNN) classifiers to discriminate between COVID-19 and CAP.
- Visual interpretation of CT scans by experienced radiologists for comparison with AI model performance.
Main Results:
- AI models demonstrated moderate diagnostic ability (AUC 0.70) in distinguishing COVID-19 from CAP.
- The best-performing model identified 8-50% of CAP patients while misclassifying only 2% of COVID-19 patients.
- Radiologists' performance in visual interpretation was also assessed.
Conclusions:
- Both human experts and AI models have a moderately low ability to reliably distinguish all COVID-19 from CAP cases based on CT imaging alone.
- Automated image analysis shows promise for identifying a significant subset of non-COVID-19 cases, supporting targeted clinical decision-making.

